# YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

> **NCT07461454** · PHASE3 · NOT_YET_RECRUITING · sponsor: **MediLink Therapeutics (Suzhou) Co., Ltd.** · enrollment: 376 (estimated)

## Conditions studied

- Locally Advanced or Metastatic Breast Cancer

## Interventions

- **DRUG:** YL202
- **DRUG:** Eribulin
- **DRUG:** Capecitabine
- **DRUG:** Gemcitabine
- **DRUG:** Vinorelbine
- **DRUG:** Sacituzumab govitecan

## Key facts

- **NCT ID:** NCT07461454
- **Lead sponsor:** MediLink Therapeutics (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-10
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 376 (ESTIMATED)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07461454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07461454, "YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT07461454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*